Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of T-cell–or natural
killer cell–derived non-Hodgkin lymphomas. The majority of patients with PTCL experience …

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas
associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert …

Purpose Preventing chemotherapy-induced nausea and vomiting (CINV) is integral to
treatment success in patients with cancer. This analysis was undertaken to assess the …

Background Palonosetron has shown efficacy in the prevention of chemotherapy-induced
nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy …

Introduction Vandetanib has recently demonstrated clinically meaningful benefits in patients
with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the …

Introduction: 5-Hydroxytryptamine3-receptor antagonists (5-HT3-RA) are the most widely
used antiemetics in oncology, and although tolerability is high, QTC prolongation has been …

As recommended by most recent antiemetic guidelines, the optimal prophylaxis of
chemotherapy-induced nausea and vomiting (CINV) requires the combination of 5-HT3 …

This review provides background information on chemotherapy-induced nausea and
vomiting (CINV) classification and pathophysiology and reviews various antiemetic agents …

Purpose This study aims to compare the efficacy and safety of oral palonosetron with
intravenous (IV) palonosetron for the prevention of cisplatin-related chemotherapy-induced …

Introduction: Ondansetron is a 5-HT3 receptor antagonist commonly used as an antiemetic
to prevent nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy or …